Background. Increasing use of the central venous catheter has become associated with catheter-related bloodstream infection due to rapidly growing non-tuberculous mycobacteria, especially in immunocompromised patients. We identified an outbreak of central venous catheter-related bloodstream infection due to Mycobacterium mucobgenicum and Mycobatereium canariasense among patients with hematologic disorders during a 5-month period.
Methods. An outbreak investigation and infection control protocol were performed at a hematology ward at a Japanese tertiary care center. We conducted a retrospective chart review and environmental investigation to identify the source of rapidly growing non-tuberculous mycobacteria and patients' outcome.
Results. A total of five patients with bloodstream infection due to rapidly growing non-tuberculous mycobacteria were identified: three patients with acute myeloid leukemia, and one patient with acute lymphocytic leukemia developed a blood culture positive for M. mucogenicum. In addition one patient with aplastic anemia developed a blood culture positive for M. canariasense. The majority of patients received cord blood transplantation prior to developing bloodstream infection. All central venous catheters in patients with bloodstream infection due to mycobacterium spp. were removed. These patients promptly defervesced after catheter removal and were successfully managed without antimicrobial therapy. With extensive environmental examination, M. mucogenicum and M. canariasensewere subsequently identified from water supplies in the hematology ward. We confirmed identification of the isolates from the bloodstream infection and environmental sources based on 16SrRNA gene sequencing.
Conclusion. The source of rapidly growing non-tubeculous mycobacteria in outbreak of bloodstream infection likely stemmed from the hematology ward tap water supply. Awareness of emerging catheter-related bloodstream infection due to mycobacterium spp. should be emphasized, especially in immunocompromised patients and treatment strategies should continue to be discussed.
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